source Fortune article The National Institutes of Health has approved a vaccine for a new virus that is resistant to some of the most popular vaccines.
The Centers for Disease Control and Prevention (CDC) said Thursday that the vaccine developed by researchers at Johns Hopkins University and the University of Pennsylvania is the first in a series of vaccines that contain a vaccine-derived strain of the virus that was resistant to the flu shot.
The vaccine will be available by the end of the year, according to a statement from the CDC.
The CDC says the vaccine is expected to have no adverse reactions in humans and no significant risk to the public.
The virus, called H5N1, has caused more than 20 million cases of respiratory and other illnesses in humans.
The virus has caused millions of deaths.
The National Institutes for Health, which has been overseeing the development of the vaccine, said it will provide additional guidance in the months ahead.
In addition to the vaccine itself, the vaccine will also contain a synthetic protein that is able to bind to a protein that controls the immune response, according the CDC statement.
That protein is produced by a group of researchers at the University at Buffalo and the Johns Hopkins university.
The new vaccine was developed by scientists at the Johns, Penn and the National Institutes, according a statement.
The Johns Hopkins researchers have been working on the vaccine since the fall of 2015.
The scientists have developed a vaccine that is made from a new type of vaccine that uses a strain of virus that has been genetically modified to be more resistant to flu shots.
In the vaccine they have developed, the virus is made to bind only to a different protein in the cell of the human immune system called an interferon-gamma receptor.
The researchers have made the vaccine from a virus that the CDC says is the most abundant in people with the flu.
The NIH said in a statement that the researchers hope to be able to test the vaccine in humans by the spring.
The vaccine will not be available for use in the United States until the fall.
The NIH said it expects that more than 2 million people will be tested and that about one-third of those tested will be vaccinated with the vaccine.
The CDC said the vaccine was tested on mice in the lab.
A study on humans will be conducted in the next six months.